Large Addressable Markets with High Unmet Needs
Efti’s three late-stage oncology programs: Lung, Head and Neck, and Breast Cancer
Non-small cell lung cancer (NSCLC)
drug market to nearly double to
$48 billion in 20312
Metastatic breast cancer (MBC)
market to reach $12.7 billion by 20246
Head and neck squamous cell carcinoma
(HNSCC) market projected to reach $3.5
billion by 2025
The above from the presso...
Two crucial aspects.....1... .EFTI has to work
2 .....Then what percentage of the addressable market will EFTI combos or EFTI itself address...
There's big money involved here if EFTI keeps ticking boxes...
Ann: Immutep Corporate Presentation, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |